Myocarditis following COVID-19 mRNA vaccination.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
29 06 2021
Historique:
received: 24 03 2021
revised: 02 05 2021
accepted: 25 05 2021
pubmed: 8 6 2021
medline: 29 6 2021
entrez: 7 6 2021
Statut: ppublish

Résumé

Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report six cases of myocarditis, which occurred shortly after BNT162b2 vaccination. Patients were identified upon presentation to the emergency department with symptoms of chest pain/discomfort. In all study patients, we excluded past and current COVID-19. Routine clinical and laboratory investigations for common etiologies of myocarditis were performed. Laboratory tests also included troponin and C-reactive protein levels. The diagnosis of myocarditis was established after cardiac MRI. Five patients presented after the second and one after the first dose of the vaccine. All patients were males with a median age of 23 years. Myocarditis was diagnosed in all patients, there was no evidence of COVID-19 infection. Laboratory assays excluded concomitant infection; autoimmune disorder was considered unlikely. All patients responded to the BNT162b2 vaccine. The clinical course was mild in all six patients. Our report of myocarditis after BNT162b2 vaccination may be possibly considered as an adverse reaction following immunization. We believe our information should be interpreted with caution and further surveillance is warranted.

Sections du résumé

BACKGROUND
Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report six cases of myocarditis, which occurred shortly after BNT162b2 vaccination.
METHODS
Patients were identified upon presentation to the emergency department with symptoms of chest pain/discomfort. In all study patients, we excluded past and current COVID-19. Routine clinical and laboratory investigations for common etiologies of myocarditis were performed. Laboratory tests also included troponin and C-reactive protein levels. The diagnosis of myocarditis was established after cardiac MRI.
FINDINGS
Five patients presented after the second and one after the first dose of the vaccine. All patients were males with a median age of 23 years. Myocarditis was diagnosed in all patients, there was no evidence of COVID-19 infection. Laboratory assays excluded concomitant infection; autoimmune disorder was considered unlikely. All patients responded to the BNT162b2 vaccine. The clinical course was mild in all six patients.
INTERPRETATION
Our report of myocarditis after BNT162b2 vaccination may be possibly considered as an adverse reaction following immunization. We believe our information should be interpreted with caution and further surveillance is warranted.

Identifiants

pubmed: 34092429
pii: S0264-410X(21)00682-4
doi: 10.1016/j.vaccine.2021.05.087
pmc: PMC8162819
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
RNA, Messenger 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3790-3793

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS One. 2015 Mar 20;10(3):e0118283
pubmed: 25793705
Eur Heart J. 2017 Sep 14;38(35):2649-2662
pubmed: 28655210
Int J Cardiol. 2018 Dec 15;273:183-186
pubmed: 30236504
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Heart Rhythm. 2020 Sep;17(9):1463-1471
pubmed: 32387246
Vaccine. 2021 Jan 29;39(5):839-845
pubmed: 33422381
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Vaccine. 2018 Mar 14;36(12):1524-1527
pubmed: 29456017
J Am Coll Cardiol. 2004 May 5;43(9):1503-10
pubmed: 15120802
J Am Coll Cardiol. 2004 Jul 7;44(1):201-5
pubmed: 15234435
JAMA. 2021 Mar 2;325(9):808-811
pubmed: 33566089
Cells. 2021 Jan 21;10(2):
pubmed: 33494237
Vaccine. 2020 Oct 27;38(46):7323-7330
pubmed: 32967791
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Saif Abu Mouch (S)

Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera, Israel; Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel. Electronic address: saif@hymc.gov.il.

Ariel Roguin (A)

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel; Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Elias Hellou (E)

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel; Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Amorina Ishai (A)

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel; Department of Imaging, Hillel Yaffe Medical Center, Hadera, Israel.

Uri Shoshan (U)

Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera, Israel; Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel.

Lamis Mahamid (L)

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel; Infectious Disease Unit, Hillel Yaffe Medical Center, Hadera, Israel.

Marwan Zoabi (M)

Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera, Israel; Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel.

Marina Aisman (M)

Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera, Israel.

Nimrod Goldschmid (N)

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel.

Noa Berar Yanay (N)

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel; Department of Nephrology, Hillel Yaffe Medical Center, Hadera, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH